Author:
Bonds D. E.,Craven T. E.,Buse J.,Crouse J. R.,Cuddihy R.,Elam M.,Ginsberg H. N.,Kirchner K.,Marcovina S.,Mychaleckyj J. C.,O’Connor P. J.,Sperl-Hillen J.-A.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference28 articles.
1. Food and Drug Administration (2011) Prescibing information Trilipix. Available from www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails , accessed 13 December 2011
2. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM (2011) Use of fibrates in the United States and Canada. JAMA 305:1217–1224
3. Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A (1999) Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 20:41–44
4. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D (2000) Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 15:1993–1999
5. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G (2005) Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45:485–493
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献